Hemato Oncology Testing Market – By Product & Service (Instrument {PCR, NGS}, Kits & Reagents, Software & Service), Cancer Type (Leukemia {Acute Myeloid, Acute Lymphoblastic}, Lymphoma {Hodgkin, Non-Hodgkin}), End-use – Global Forecast 2024 – 2032

Hemato Oncology Testing Market Size

Hemato Oncology Testing Market size was valued at USD 3.2 billion in 2023 growing at a CAGR of 14.2% from 2024 to 2032.  The market's growth is primarily fueled by the rising prevalence of hematological malignancies, such as myeloma and lymphoma, driving an increased demand for specialized diagnostic tests.
 

For example, a report from the American Cancer Society highlights that non-Hodgkin lymphoma (NHL) ranks among the most prevalent cancers in the U.S., constituting roughly 4% of all cancer cases. Moreover, the report notes that in 2023, approximately 80,620 individuals (44,590 males and 36,030 females) received NHL diagnosis. Consequently, advancements in diagnostic technology, coupled with heightened awareness of hematologic cancers and the advantages of early detection, have spurred a rise in screening and diagnostic testing, further propelling the market's growth.
 

Hemato oncology testing is a specialized medical diagnostic field dedicated to detecting, diagnosing, and monitoring blood-related cancers, including leukemia, lymphoma, and multiple myeloma. These tests aim to pinpoint genetic mutations, chromosomal abnormalities, and other biomarkers linked to hematologic malignancies.
               

Hemato Oncology Testing Market Trends

Innovations in molecular diagnostic technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH), have improved the accuracy and speed of hemato oncology testing, driving market growth during the analysis period. For example, the National Comprehensive Cancer Network and the European LeukemiaNet guidelines for chronic myelogenous leukemia (CML) endorse the RT-qPCR test for diagnosis confirmation. They recommend the RT-qPCR test every 3 months until BCR-ABL1 transcripts drop below 0.1%, then every 3 to 6 months. This increases the use of PCR-based assays, given their high sensitivity in detecting genetic mutations in patient blood samples and bone marrow. Furthermore, advancements in diagnostic technology facilitate personalized medicine approaches, increasing the demand for hemato-oncology testing and contributing to market growth.
 

Hemato Oncology Testing Market Analysis

Based on the product & service, the market is classified into instrument, kits & reagents, and software & services. The instrument is further bifurcated into next generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, cytogenetics, immunohistochemistry, and other technologies. The kits & reagents segment dominated the market with revenue of USD 1.7 billion in 2023.
 

• The rising demand for personalized medicine, which tailors treatments to a patient's genetic and molecular profile, significantly boosts the need for specialized diagnostic kits and reagents, fueling market growth.
   
• Furthermore, ongoing R&D in hematology diagnostics propels the demand for enhanced testing kits and reagents, further stimulating market expansion.
   
• Additionally, regulatory bodies like the FDA and EMA consistently approving new diagnostic tools and reagents. Their updated guidelines advocate for advanced testing methods, further propelling market growth.
   

Based on the cancer type, the global hemato oncology testing market is segmented into leukemia, lymphoma, and other cancer types. The leukemia is further bifurcated into acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The lymphoma is sub-segmented into Hodgkin lymphoma, and non-Hodgkin lymphoma. The lymphoma segment dominated the market with market share of 51.3% in 2023.
 

• The rising incidence of lymphoma, including both Hodgkin's and non-Hodgkin's lymphoma, coupled with increasing awareness and improved diagnostic techniques, has contributed to a higher number of diagnosed cases, driving the growth of the market.
   
• In addition, the implementation of more comprehensive screening programs helps identify lymphoma at an earlier stage, leading to a higher demand for non-Hodgkin lymphoma diagnostic tests, thereby fuelling market growth.
   

Based on end-use, the hemato oncology testing market is classified into hospitals & clinics, diagnostic laboratories, and other end-users. The diagnostic laboratories segment is expected to exhibit 14.5% CAGR between 2024-2032.
 

• The increase in investment to improve the healthcare infrastructure by upgrading and expanding diagnostic laboratories enhances testing capabilities and capacity, thereby contributing to the growth of the market.
   
• Moreover, the increase in the number of partnerships between diagnostic laboratories and research institutions improves testing standards. This collaboration fosters innovation and enhances the diagnostic laboratories as centers of excellence in hemato oncology testing, thereby fostering market growth.
   

In 2023, North America held a commanding 45.6% share of the global hemato oncology testing market, a trend poised to continue throughout the forecast period.
 

• In the U.S. and Canada, the rising rates of hematological cancers, including leukemia, lymphoma, and multiple myeloma, fuel the demand for advanced diagnostic and monitoring tests, propelling market growth.
   
• North America's leading healthcare facilities and research institutions swiftly adopt cutting-edge hemato oncology testing technologies.
   
• Ongoing clinical trials in North America for new hemato oncology treatments and diagnostics heighten the demand for testing services, further driving market growth.
   

These factors solidify North America's leading position in the hemato oncology testing market.
 

The U.S. hemato-oncology testing market is projected to grow at a robust CAGR of 14.1% from 2024 to 2032.
 

• Advancements in healthcare infrastructure and supportive reimbursement policies facilitate the uptake of modern testing technologies. Insurance coverage and favorable reimbursement rates for hematology oncology tests motivate healthcare providers to utilize them.
   
• Moreover, regulatory endorsements for novel testing methods and innovations in diagnostics bolster market expansion. The U.S. Food and Drug Administration (FDA) significantly influences market dynamics through its test approvals.
   

Germany is set to lead the growth in Europe's hemato oncology testing market.
 

• Germany's advanced healthcare system, bolstered by significant investments in medical research and diagnostics, fosters the adoption of state-of-the-art diagnostic tests.
   
• The German government actively backs cancer research and the evolution of novel diagnostic methods with funding and grants. Initiatives like the German Cancer Aid and national research programs play pivotal roles in advancing hemato oncology testing.
   

The Asia Pacific region anticipates a notable CAGR of 14.7% in its hemato oncology testing market during the forecast period.
 

• Growth in the Asia Pacific's hematology-oncology testing market is buoyed by expanding healthcare infrastructures, including hospitals and diagnostic labs.
   
• Additionally, the surging elderly population in nations like India, Japan, and China, who are more susceptible to hematologic malignancies, amplifies the demand for diagnostic testing.
   

Hemato Oncology Testing Market Share

The market is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts are aimed at enhancing their product and service offerings, expanding their geographic reach, and investing in advanced technologies. The market also witnesses the entry of new players, intensifying the competitive landscape further.
 

Hemato Oncology Testing Market Companies

Prominent players operating in the hemato oncology testing industry are as mentioned below:

• Abbott Laboratories
• ARUP Laboratories
• Bio-Rad Laboratories Inc.
• Danaher Corporation (Integrated DNA Technologies, Inc.)
• Entrogen Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Invivoscribe, Inc.
• Invitae Corporation (Archerdx, Inc.)
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Vela Diagnostics
   

Hemato Oncology Testing Industry News:

• In January 2024, Agilent Technologies Inc. announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio. This collaboration will enable Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development.
   
• In March 2023, Servier announced it has entered a strategic partnership with QIAGEN. QIAGEN and Servier are collaborating to develop a PCR-based companion diagnostic test that can be used to rapidly identify AML patients with IDH1 gene mutations. Thus, this partnership will lead to the development of a specific diagnostic test for IDH1 gene mutations with a rapid turnaround time.
   

The hemato oncology testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product & Service

• Instrument
  • Next-generation sequencing (NGS)
  • Polymerase chain reaction (PCR)
  • Flow cytometry
  • Cytogenetics
  • Immunohistochemistry (IHC)
  • Other technologies
• Kits & reagents
• Software & services

Market, By Cancer Type

• Leukemia
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Chronic lymphocytic leukemia (CLL)
  • Chronic myeloid leukemia (CML)
• Lymphoma
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma (NHL)
• Other cancer types

Market, By End-use

• Hospitals & clinics
• Diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa